43 results on '"G.T. Everson"'
Search Results
2. HCV Eradication Results in Reduction of Hepatic Venous Pressure Gradient 48 Weeks after End of Treatment; Final Results of the Study of Sofosbuvir plus Ribavirin in Patients with Cirrhosis and Portal Hypertension
3. Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis
4. Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study
5. P0774 : Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: An integrated safety analysis of the solar 1 and solar 2 trials
6. P0814 : Hepatic improvement in response to ledipasvir/sofosbuvir/ribavirin as measured by the hepquant® (HQ)-shunt test in liver transplant (LT) recipients with allograft fibrosis or cirrhosis and non-LT patients with decompensated cirrhosis
7. P0872 : Early viral kinetics do not differ in patients with varying degrees of fibrosis and cirrhosis in the solar 1 trial
8. LP13 : Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension
9. O008 : Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child–pugh class B cirrhosis (C-salt part A)
10. On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1–6 HCV Infection Treated with Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the Astral-1, Astral-2, and Astral-3 Studies
11. O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS
12. P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation
13. O007 : All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience
14. 23 A MULTICENTER STUDY OF PROTEASE INHIBITOR-TRIPLE THERAPY IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS: REPORT FROM THE CRUSH-C GROUP
15. 715 NON-INVASIVE CHOLATE TESTING PREDICTS RESPONSE TO PEGINTERFERON/RIBAVIRIN AND MEASURES FUNCTIONAL IMPROVEMENT AFTER SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C
16. 1207 TRIPLE THERAPY WITH DACLATASVIR (DCV; BMS-790052), PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV-INFECTED PRIOR NULL AND PARTIAL RESPONDERS: 12-WEEK RESULTS OF PHASE 2B COMMAND-2 TRIAL
17. 10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB
18. 1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS
19. 1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12
20. 1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS
21. O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY
22. O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION
23. 2006 GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN SIGNIFICANTLY IMPROVES VIROLOGIC RESPONSE AND ALT NORMALIZATION AT END-OF-TREATMENT AND IMPROVES SVR24 COMPARED TO PEG-IFN/RIBAVIRIN IN GENOTYPE-1 CHRONIC HCV PATIENTS
24. 765 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RESPONSE (RPCDBDR) TRIAL OF CTS-1027, AN INHIBITOR OF MATRIX METALLOPROTEASES (MMPS) IN PATIENTS WITH HCV WHO HAD FAILED PRIOR THERAPIES
25. 627 GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES
26. 3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY
27. 1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)
28. 1423 INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS
29. 818 HCV-TARGET: A LONGITUDINAL, OBSERVATIONAL STUDY OF NORTH AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH BOCEPREVIR OR TELAPREVIR
30. 13 COMBINATION OF THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION
31. 815 FACTORS ASSOCIATED WITH INTOLERANCE TO PEGINTERFERON alfa/RIBAVIRIN IN TREATMENT-NAÏVE, CIRRHOTIC/NON-CIRRHOTIC HCV GENOTYPE 1-INFECTED PATIENTS: ANALYSIS OF DATA FROM THE MULTINATIONAL PROPHESYS COHORTS
32. 1415 CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS
33. 410 24-WEEK TREATMENT WITH CTS-1027 IN COMBINATION WITH RIBAVIRIN REDUCES HCV-RNA IN TREATMENT NAIVE GENOTYPE-1 PATIENTS
34. 468 UNIQUE PATTERN OF VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE-1 HCV: A PHASE II STUDY OF CTS-1027 IN COMBINATION WITH PEGINTERFERON/RIBAVIRIN (SOC) IN NULL RESPONDERS
35. 1181 PHARMACOGENOMIC ANALYSIS REVEALS IMPROVED VIROLOGIC RESPONSE IN ALL IL-28B GENOTYPES IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS TREATED WITH GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN
36. 1189 ONCE-DAILY NS5A INHIBITOR (BMS-790052) PLUS PEGINTERFERON-ALPHA-2A AND RIBAVIRIN PRODUCES HIGH RATES OF EXTENDED RAPID VIROLOGIC RESPONSE IN TREATMENT-NAIVE HCV-GENOTYPE 1 SUBJECTS: PHASE 2A TRIAL
37. 277 GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN IMPROVES BIOPSY NECRO-INFLAMMATORY SCORES AND ALT NORMALIZATION AT 48 WEEKS VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV PATIENTS
38. 66 POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR R7128 WITH PEG-IFN AND RIBAVIRIN: INTERIM RESULTS OF R7128 500MG BID FOR 28 DAYS
39. 4 PROVE1: RESULTS FROM A PHASE 2 STUDY OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH HEPATITIS C
40. 993 HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN
41. [786] RESULTS OF AN INTERIM ANALYSIS OF A PHASE 2 STUDY OF TELAPREVIR (VX-950) WITH PEGINTERFERON a-2a AND RIBAVIRIN IN PREVIOUSLY UNTREATED SUBJECTS WITH HEPATITIS C
42. 456 Safety, pharmacokinetics and pharmacodynamic results of higher doses of albuferon in a phase single and double dose-escalation study in treatment experienced subjects with chronic hepatitis C
43. 313 A 1/2phase study to evaluate the pharmacokinetics, safety, tolerability, immunogenicity, and pharmacodynamics of albuferon™ in the treatment experienced subjects with chronic hepatitis C
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.